Conduct↦Safety↦Safety and Protective Measures↦Procedures
What is it? Why is it important?
Safety and Protective Measures (SPM) are activities implemented without delay to ensure the protection of study participants including other involved persons against:
- Suspected new risks potentially able to jeopardize their safety
Based on safety concerns, the implementation of SPMs are required, defined, and documented for both HRO and ClinO studies.
During study conduct, the SP-INV can decide to include a Data Safety Monitoring Board (DSMB). Based on data review and risk analysis, the DSMB can provide support regarding the optimal implementation of SPM.
What do I need to do?
As a Project-Leader of an HRO research project, report any immediate SPMs to EC (via BASEC):
- Within 7 days, and describe:
- Circumstances that led to the implementation of SPM
- The nature of the SPMs
As a Site-INV of a ClinO study, report any immediate SPM and its root cause to:
- The SP-INV within 24 hours
- EC via BASEC within:
- 7 days, for IMP studies
- 2 days, for in vitro diagnostic IMD studies
As a SP-INV of a ClinO or ClinO-MD study, report any immediate SPM and its root cause to:
- EC via BASEC, and
- Swissmedic for risk category B and C studies within:
- 7 days for IMP studies
- 2 days, for IMD studies
- 24 hours if the termination / interruption of an IMD study was due to safety reasons
For investigational studies of risk category A, report to Swissmedic via the:
- Pharmacovigilance reporting system for studies with an IMP
- Materiovigilance reporting system for studies with an IMD
More
Reports should include a detailed description of the nature and circumstances that required the implementation of SPM.
In the event of multi-centre EU or EEA studies, the SP-INV must also notify all other participating ECs within the same deadlines.
Where can I get help?
Your local CTU↧ can support you with experienced staff regarding this topic
Basel, Departement Klinische Forschung, CTU, dkf.unibas.ch
Lugano, Clinical Trials Unit, CTU-EOC, www.ctueoc.ch
Bern, Clinical Trials Unit, CTU, www.ctu.unibe.ch
Geneva, Clinical Research Center, CRC, crc.hug.ch
Lausanne, Clinical Research Center, CRC, www.chuv.ch
St. Gallen, Clinical Trials Unit, CTU, www.kssg.ch
Zürich, Clinical Trials Center, CTC, www.usz.ch
External Links
Swissethics – see in particular
- Templates and checklists / Notifications
Swissmedic – see in particular
- Human medicine
- Clinical trials on medicinal products
- Safety measures in clinical trials
- Medical devices
- Clinical trials
- Submissions during ongoing clinical trials
References
ISO 14155:2020 Medical device (access liable to cost) – see in particular section
- 3.46 Serious health threat
Swiss Law
ClinO – see in particular article
- Art. 37 Notification of safety and protective measures
ClinO-MD – see in particular article
- Art. 34 Reporting of safety and protective measures
HRO – see in particular article
- Art. 20 Notification of safety and protective measures